PRO-513 is a patented formulation of diclofenac potassium powder for oral solution, which has been demonstrated to enhance the pharmacokinetic profile of diclofenac. This formulation is expected to offer a new safe and efficacious prescription alternative for migraine patients.
Carl Whatley, chairman and CEO of ProEthic, said: “I am ecstatic about this milestone and I am so very proud of our ProEthic team for a job well done.”